Technology ID
TAB-3709
Stable SVG Cell Lines for Studying JCV Infection and Progressive Multifocal Leukoencephalopathy
E-Numbers
E-151-2012-0
Lead Inventor
Major, Eugene (National Institute of Neurological Disorders and Stroke)
Co-Inventors
Ferenczy, Michael (National Institute of Neurological Disorders and Stroke)
Marshall, Leslie (National Institute of Neurological Disorders and Stroke)
Jensen, Peter (National Institute of Neurological Disorders and Stroke)
Steinberg, Shannon (Dartmouth College)
Applications
Vaccines
Research Materials
Therapeutic Areas
Neurology
Lead IC
NINDS
This invention relates to the derivation of two stable cell lines, SVG5F4 and SVG1OB1, which can be used to study JC-virus infection. SVG cells are a heterogeneous population of immortalized human fetal glial cells, which express SV40 large T antigen. They are capable of supporting JC virus infection; however, the culture is mixed and changes over time. The two SV40-derived cell lines described here are stable over many passages. SVG5F4 cells have a greatly reduced ability to support JCV infection, while SVG10B1 cells support robust infection and can maintain persistent JCV infection over several months (unlike SVG cells, in which susceptible cells are depleted by persistent infection). These cells will provide tools to study JCV and cellular differences in JCV infection. In addition, there is currently no available treatment for the often-fatal disease caused by JCV: Progressive Multifocal Leukoencephalopathy.
Commercial Applications
The SVG10B1 cells can provide a platform for anti-JCV drug studies and are potentially useful to grow JCV vaccines.
Competitive Advantages
The SVG4F4 cell line is uniquely capable of maintaining a stable JCV infection over the course of several months.
Licensing Contact: